Pediheart: Pediatric Cardiology Today

This week we review the results of one of the rare placebo controlled double blind trials of an agent in pediatric cardiovascular medicine - specifically, the Fontan Undenafil trial assessing the impact of this agent on parameters of exercise in the single ventricle patient. What measures of exercise were most affected by this agent and why? What side effects were encountered? Who should receive these agents? These are amongst the many questions we tackle with the first author, Dr. David Goldberg of The Children's Hospital of Philadelphia. doi: 10.1161/CIRCULATIONAHA.119.044352